Drugs / SGN-CD19B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02702141 | Feb 2016 → Jul 2018 | diffuse large B-cell lymphoma | Seagen Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGN-CD19B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02702141 ↗ |
| Action | Deplete | “CD19-expressing tumor cells rapidly internalize SGN-CD19B, and the released PBD drug induces DNA damage, resulting in G2/M cell cycle arrest and cell death.” PMID 28903943 ↗ Sep 2017 |
| Modality | Other / unclassified | “anti-CD19 antibody drug conjugate (ADC)” PMID 28903943 ↗ Sep 2017 |
| Route | Intravenous | “Given intravenously Day 1 of 28-day or 42-day cycles” NCT02702141 ↗ |
| Target | CD19 | “anti-CD19 antibody drug conjugate (ADC)” PMID 28903943 ↗ Sep 2017 |